{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-004967","form_type":"8-K","ticker":"AVBP","cik":"0001868279","company_name":"ArriVent BioPharma, Inc.","filed_at":"2025-01-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.414460+00:00","generated_at":"2026-05-27T21:00:55.764027+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ArriVent licenses ADC MRG007 from Lepu Biopharma; upfront $47M, total potential $1.16B","bullets":["Exclusive global rights outside Greater China for MRG007, a preclinical ADC targeting GI cancers.","Lepu Biopharma receives $47M in upfront and near-term milestones; eligible for up to $1.16B in total milestones plus tiered royalties.","First IND submission planned for first half 2025; initial focus on CRC, pancreatic, and other GI cancers.","ArriVent’s previously announced cash runway into 2026 remains unchanged despite upfront and R&D costs.","MRG007 showed robust antitumor activity and favorable therapeutic index in preclinical and IND-enabling studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-004967","json":"https://secwatch.observer/filing/0001104659-25-004967.json","markdown":"https://secwatch.observer/filing/0001104659-25-004967.md","text":"https://secwatch.observer/filing/0001104659-25-004967.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1868279/000110465925004967/0001104659-25-004967-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1868279/000110465925004967/tm253966d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T21:00:55.764027+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}